步长制药：获得药品补充申请批准通知书

Core Viewpoint - Company has received approval from the National Medical Products Administration for the drug "Xiaolinbaituxian," which will enhance product quality and meet market demand, positively impacting future operations [1][2]. Group 1: Drug Approval and Details - The drug "Xiaolinbaituxian" has been approved for marketing, with the original approval number remaining unchanged [1]. - The marketing authorization holder has been changed from "Shandong Kongfu Pharmaceutical Co., Ltd." to "Shandong Buchang Pharmaceutical Co., Ltd." [1]. - The drug is used for clearing heat and detoxifying, particularly for symptoms related to lower urinary tract infections [1]. Group 2: Research and Development Investment - The company has invested approximately 28.15 million RMB in research and development for "Xiaolinbaituxian" and its pill form [1]. - The company emphasizes the importance of quality and safety in drug research, manufacturing, and sales [2].